Sanofi‘s most advanced multiple sclerosis drug candidate failed to achieve the main goal of two late-stage trials to treat relapsing forms of the disease. However, the drug was able to succeed in a ...

After previous disappointments with BTK inhibitors, a novel drug in this class is the first to show superiority to an active ...

Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing multiple ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Tyruko, the first biosimilar to Tysabri injection, for the treatment of adults with ...

For patients with relapsing-remitting multiple sclerosis (MS), rituximab is not noninferior to ocrelizumab, according to a study published online June 12 in JAMA Neurology. Izanne Roos, M.B.Ch.B., ...

An experimental stem cell therapy proved effective and safe in patients with a relapsing form of multiple sclerosis (MS), an autoimmune disease that affects the central nervous system, new research ...

Antibiotic resistance continues to push modern medicine into dangerous territory. In hospitals around the world, infections ...

A breakthrough in monkey malaria research could help scientists diagnose and treat a relapsing form of human malaria. A breakthrough in monkey malaria research by two University of Otago scientists ...